Obesity Solutions Like Weight Loss Drugs To Act As Catalyst For Economic Surge, Goldman Sachs Forecasts
Portfolio Pulse from Vandana Singh
Goldman Sachs economists predict a 1% boost to the US GDP from the widespread use of weight-loss drugs, specifically GLP-1 agonists. The market for these drugs, led by Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, is expected to reach $100 billion annually by 2030. The increase in GLP-1 usage could significantly reduce obesity-related complications and improve workplace efficiency, potentially elevating US GDP by 1.3% or $360 billion annually.
February 23, 2024 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly, producer of Mounjaro, is a major competitor in the rapidly growing GLP-1 agonist market, which is forecasted to significantly contribute to the US GDP.
Eli Lilly is highlighted as a significant player in the weight-loss drug market through its production of Mounjaro. The anticipated market expansion and its contribution to the US GDP growth indicate a positive outlook for Eli Lilly's financial performance and stock valuation.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Novo Nordisk, with its leading GLP-1 agonist Ozempic, is positioned at the forefront of a market expected to reach $100 billion annually by 2030, potentially boosting the US GDP by 1%.
As the creator of Ozempic, one of the leading GLP-1 agonists, Novo Nordisk is directly mentioned as a key player in the expanding market for weight-loss drugs. The expected market growth to $100 billion by 2030 and the potential GDP boost underscore the significant impact on Novo Nordisk's financial outlook and stock performance.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90